Clinical trial
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated…
NCT00003248 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003248 |
|---|---|
| Title | Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia |
| Official title | A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) [NSC# 687451] Induction Followed By Rituximab Consolidation In Untreated Patients With B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | rituximab, fludarabine phosphate |
| Enrollment | 104 |
| Start date | Mar 1, 1998 |
| Primary completion | Apr 1, 2003 |
| Completion | Jun 1, 2010 |
| First posted | Sep 10, 2004 |
| Last update posted | Jul 20, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: